Subject Index

aberration rates 47, 48, 113 accidents, actually occured in nuclear

power plants 89 Idaho Falls 1961 90 Los Alamos 1945 89 Los Alamos 1946 89 Los Alamos 1958 89 Oak Ridge 1958 89 Vinca, Yugoslavia 1958 90

air traffic 9 collective dose equivalent of the

world population 9 dose rate per person using super­

sonic aircraft transport 9 animal studies on the protection of ma­

lignant tissues by radioprotective drugs 122

annual limit of intake (ALI) 32,36-41 antimutagenic efficacy of radioprotec­

tors 113 against chromosome damage 113,

114 against lethal mutations 113 decrease induction of abberations

114 areas with increased terrestrial radia­

tion 3,7

BEIR 28 bone seeker 8

cancer mortality, 1976-2070 42 effects of carcinogens or ionizing

radiation 42 cancer mortality and radiation dose,

correlation 66 chemical radioprotection 97 - 132

effect of radiation type 119 high LET, neutrons 119, 120 low LET, X-rays or y-rays 119

gastrointestinal death 104, 119 hematopoietic radiation death 104,

105, 119 hematopoietic radiation syndrome

104,105, 119 in mammals 97-123, 126-132 in man 97,101,102,123-126,131,

132 Chernobyl accident 75, 79, 80, 82,

90-92 RBM K-1 000, characteristics 80

Chernobyl accident, medical measures 79, 80, 82, 90-92 blood transfusion 91,92

bone marrow transplantation 88, 91

firemen members of the general po­pulation 90

hospital wards under aseptic condi­tions 91

patients classified into four groups by degree of injury 90

prevention of endogeneous infec­tions, antibiotics 91

prophylaxis and treatment of infec­tions 87,91

substitution of platelets and erythro­cytes 87,91,92

workers at the plant 90 chromosomal diseases 47,48, 113 collective dose equivalents 29 combined injuries: radiation effects,

burns and/or wounds 117 animal mortality studies 117 benefit of radioprotective agents

117 burn 117-119 injuries in animals by skin

wounds, superficial burns, and whole-body irradiation 117-119

irradiation 117 - 119 skin wound 117-119 whole-body irradiation and surgi-

cal operations 119 committed dose equivalents 36, 50 core melting 75, 78, 79 cosmic radiation 2, 9

absorbed dose rate 9 dependency on geographic latitude

and sun activity 9 dose equivalent rate 9 energy spectrum 2 exposure during flights at high altitu­

des 9 exposure during space travel 9, 10 increase with height above sea level

9 neutron flux density 2 primary 2,9 secondary 2 solar flares 2, 9 solar galactic radiation 9 total dose equivalent 2 van Allen radiation belts 9

critical organ 34 cystamine tablets in the ABC selfpro­

tection kit 124

diagnosis of radiation injuries 27, 86, 87

direct and indirect radiation effects, in-fluences of radioprotectors 121, 127

dose equivalents 30, 33, 36, 50 dose equivalent commitment 35,36 dose equivalent limit (L) 30-33,35,

36 external exposure 32

deep dose equivalent index 32 internal exposure 32 total stochastic risk for nonuniform

whole body exposure, weighting factors 32, 36

uniform whole body exposure 32 dose fractionation 45 dose limitations 28, 29 dose limits proposed by ICRP 26,29,

43, 73 dose modification factor 98, 107 dose protraction 45 dose reduction factors (DRFJ 98,99,

103, 106, 120 comparison of radioprotective

agents 98 definition 98 dose-effect relationship, criterion

death or survival 98, 108, 109 gastrointestinal injury 119

neutrons 119, 120 relative efficacy of radioprotective

chemicals 98 survival curves, rates 98, 102, 103

dose-response relationships 26, 29, 43-45 consequences to risk estimations 43,

45 hormesis at low doses 44 linear dose relationship 43, 45 linear quadratic relationship 44, 47,

79 linear relationships without thresh­

old 43,45 quadratic relationship 44 relationship with exponent smaller

than 1 45 threshold for stochastic effects 44

DRF 98,99, 103, 104

effective dose equivalent 31-33,35, 36

effects from low dose exposures 43 embryotoxicity of radioprotective

agents 114

146

emergency measures for nuclear power plants 80- 82 early phase 81, 85

dose equivalent levels 81 intermediate phase 81, 85 levels of alarm 80

emergency alarm 81 emergency warning 80 special alarm - water 81

nuclear risk potential 80 permissible radioactivity levels in

food 80 phases of a serious accident 81, 85 radioactivity in the environment 81 recovery phase 81

emergency station, organizational structure 88 contamination measurements 88 medical examination 88 registration interview 88

energy production, radiation exposure coal-fired power plants 19

emissions of radioactive substan­ces 19,20

radioactive substances in the fly ash 19

radioactivity concentration in coal 19

oil, natural gas, and geothermic energy 20

epidemiology of occupational radiation hazards 46, 48, 62 analytical methods 62 case control studies 62 cohort studies 62 comparison groups 62 confounding factors 63

age, sex, ethnic group 63 calendar year 63 distribution of exposure doses 63 effect doses within the range of na-

tural radiation exposure 63 temporal pattern of incidence and

mortality 63 nested studies 62

estimation of risks 31 comparisons of radiation exposure

with other occupational risks 31, 41,42,61 fatal malignancy 32 mean annual mortality 31,41

exposure outdoors 3, 4, 12 annual effective dose equivalent 3

fission products 76- 78 fallout 75, 76 from a nuclear weapon explosion

75, 76 in the core of a reactor 76

genetic significant dose 50 German reactor safety study 77,83

healthy worker effect 62,68, 71 high thorium or uranium concentration

in the soil, regions 3, 7

Hiroshima and Nagasaki 46,47,61, 64, 92 combined injuries 92 effects of revision of the dosimetry

47 cancer induction 47 chromosome aberrations 47 development of the brain 47

follow-up studies 47 animal experiments 47

hereditary effects 45,47,48 survivors 46,47,61,64,92

hospitals for treatment of very serious forms of radiation injury 89

human epidemiological studies 46,61, 64, 73

ICRP risk factors 42,45-48, 73 incorporation of radioactive substan­

ces 32,35 19 interactions between chemicals and

radiation 98 antagonism "radioprotection" 98 enhancement "sensitization" 98

internal irradiation by radionuclides 3-8

International Commission on Radiolo­gical Protection (ICRP) 28,61 committees 28 publications, statements and recom­

mendations 28, 84 irregular diseases 47, 48 irregularly inherited diseases 47, 48

LDso (radiation dose for 50% lethality) 98-100

limits of dose equivalents for work 30, 32,33 annual limits for workers 33 category A and category B 33 special working conditions 33

accidents 33 extraordinary events 33 medical applications 33 pregnant women 33

workers under 18 years of age 33 limits of radiation exposure 30,61,71

comparing risk with that for other occupations 31, 41, 42, 61

epidemiologic studies 46,61,64 linked diseases 47, 48 lung cancer in miners 17,49,63

Schneeberg disease 63 lung cancer risk in mines 17,49,63,64 lung cancer risk for population 17,18,

63-65

medical problems after a reactor accident 87 - 89 decontamination 87 first-aid measures 87 help of regional radiation protection

centers 87 medical care for workers 87

diagnostic procedures 89 outpatient care 89

Subject Index

therapeutical measures 87 miners, radiation carcinogenesis 17,

49,63,64 mutagenicity, radiation-induced 47,48

linear relationships without thresh­olds 43,45,47,79

mutscheller dose 25

natural external radiation exposure 2 natural internal radiation exposure

3-8 non stochastic effects 28, 36, 84 non stochastic somatic effects 28,31,84 nonuniform whole body exposure,

weighting factors for tissues 32, 36 nuclear bomb explosions, combined in­

juries 75, 92-94 additional trauma 93 animal experiments 92 combination of burns with radiation

doses 92 combined injuries, trauma, infec­

tions, wound, burns, severe ex­haustion, or stress 92

effect of open skin wounds 93 medical care 92 pathology and management of

injuries 92 recommendations caring for patients

with combined injuries: wound ex­cision 93 surgery 94 tolerance to drugs 94

nuclear industry, radiation carcinogene­sis 49,67 all workers summed up 73

myeloma in Hanford and Sella­field, significant trend 73

epidemiologic methods 67 Hanford study 49, 67

all malignant tumors 68 brain tumors 68, 70 carcinoma of the pancreas 68, 70 comparison with natural radiation

exposure 69 doubling doses and the latency of

the different tumors 68 frequency of leukemia and cancer

67 higher radiosensitivity of the work­

er over 40 68 lung cancer 68 methods used in the analysis of the

Hanford data 69 myeloma 68, 70

Oak Ridge National Laboratory study 70 carcinoma of prostate 70 external radiation exposure 70 Hodgkin's disease 70 incorporation of radioactive sub-

stances 70 leukemia 70 mortality compared with popula­

tion of the USA 70 myeloma 70

Subject Index

Sellafield study 70-72 cancers of liver, gallbladder, and

lung 71 comparison of causes of death

among Sellafield workers with those in the population 71

Hodgkin's disease 71 leukemia 71 mortality from bronchitis 71 myeloma 71

shipyard workers study 72 building and overhauling nuclear

submarines 72 leukemia deaths 72

UKAEA study, Atomic Energy Authorities 72 bladder cancer 72 brain tumor 72 cancer of the prostate 72 death among the employees in

comparison with the national cancer mortality 72

lung cancer 72 stomach cancer 72

occupational exposure, dose limita­tions 26, 28, 43, 73

occupational exposure, dose equivalent limits 30,32,33,50,61 linear energy transfer (LET) 30 quality factor 30

occupational exposure to radiation 26, 61 causes of death up until 1959 26,61

occupational exposures, measurement and statistical statements 48-53 control measurements of laboratory

air 52 cost-benefit analyses 29, 50 dose-controlled workers and plants

29,49,51 nuclear plants 51, 52 workplaces 29,49,51

exposures of fingers 52 external doses, results for incorpora­

tion 50 body counters 50 urine samples 50, 51

inhalation and incorporation of a-emitters 49 persons handling radon therapeu­

tically 49 radium dial painters 49, 67 studies on workers in uranium

plants 49 workers in the Hanford plutomi­

um plants 49, 67 results of exposure control 50, 52

industrial radiography 52 industry 52 medical research 52 nuclear medical practice 52 nuclear plants 51, 52 radioimmunoassay techniques 52 radiopharmaceutical laboratories

52

statistical studies comparing exposed and nonexposed workers 48, 62 carcinogenic effects 48, 61, 62 determining the rates of chromo-

some aberration 49 frequency of dermatitis and skin

cancer 49,61,65 workers exposed during working

Jives 46,48 occupational exposures, quantification

of risks 41-48,61-73 comparison with other industries

31,41,42,61 loss of working hours 42 manifestation of malignancy 41,

42,61 ICRP concept, index of harm 41,42

admissibility for low dose range 42

occupational risks of exposures 26, 28 ALARA 28-30,41 figures for limits 28 (CRP system of dose limitation 29 principles and practices 28 risks of harm within limits 28

oxygen enhancement ration (OER) 121

210Pb 8 phosphate ores, radiation exposure 18

by-product gypsum 19 phosphate fertilizers 18

4OK, 226Ra, 2J2Th concentrations 18,19

phosphoric acid 19 21OpO 8 pulmonary radiation syndrome 110

126Ra, radioactive decay properties 13 Ra and Th in building materials 15 radiation accidents, medical aspects

75-94 radioactivity, release 76

barriers to prevent release of fission products 77

reactor accidents 75 core melting 75 nuclear weapons testing 75 radioactive substances from nucle-

ar bomb explosions released and deposited as ,,fallout" 75, 76, 79

radioactive substances from reac­tor accidents released and depo­sited as "fallout" 75, 76, 79

radiation carcinogenesis 41-48, 61-78 radiation, directly ionizing 2 radiation dose for 50% lethality =

LDso 98-100 radiation dose and rate of mutations

25 doubling dose 25 proportionality 25

radiation doses 1 natural range 1 technologically modified 1, 8-22

unmodified 1-8,21,22 external 2, 3 internal 2-8

radiation effects 26,27,86, 87 nonstochastic 26-28

threshold values 26 thresholds 28, 31, 84

147

radiation effects after whole-body exposure 27, 86, 104 cardiovascular manifestations 87,

104 central nervous system death 104 diarrhea 104 gastrointestinal death 104, 119 gastrointestinal symptoms 104, 119 hematopoietic death, syndrom 104,

119 radiation exposure, natural 1-24

technologically modified 8-22 by building materials 9 by coal and burning 8 by flights at high altitudes 9

radiation exposure, non-natural 1 radiation, indirectly ionizing 2 radiation injury after total body expo-

sure, radiation syndrome 26, 85-89 blood lymphocyte count decreases

87 bone marrow failure 87 damage of the intestinal mucosa 87 diarrhea 87 disturbances in hemopoiesis in the

damaged bone marrow 85 effects on the central nervous system

and cardiovascular system 87, 104 relationship between radiation dose

and early symptoms 87 symptom-free latent time 86

radiation protection 29,50, 51, 97 -132 ALARA 28-30,41 cost-benefit analysis 29, 50

gross benefit 29 net benefit 29, 84

exposure control 29, 49 external and internal exposures 29

diagnostic radiology 30 nuclear medicine 30 radiotherapy 30

facilities 50 international and national commit­

tees 30 operational problems 51 optimization 29, 50

radiation protection of reactor staff and general popUlation 84 decontamination of ground, roads,

and buildings 85 early phase 81, 85 individual doses, collective doses 85 intermediate phase 85 intervention levels in emergency

plans 85 phases of a serious accident 81, 85 recommendations of the (CRP 28,84 recovery phase 81, 85 variety of accident scenarios 84

148

radiation syndrome 26,85,87,89,90, 92 bone marrow transplantation 88, 91 substitution treatment with granulo-

cytes and thrombocytes 87,91 symptoms and prognoses 26, 27 therapy with antibiotic drugs 87, 91

radiation victims 26, 61 radioactive iodine released during reac­

tor accident 82 accumulation in the thyroid gland

82 distribution of iodide tablets after ac-

cident 82 incorporation 82 recommended dose 82 risk of induction of hyperthyroidism

and thyrotoxicosis 83 radioactivity, release in an accident 75,

76,79 factors affecting danger to people

77 contamination of the body

surface 77 external body irradiation 77 internal radiation exposure 77

radiodermatitis 26, 28, 61 radiologists, radiation carcinogenesis

65,66 cancer of pancreas 47,65,66 cancer risk in radiologic technolo-

gists related to radiation dose 66 leukemia 65, 66 mortality from skin cancer 49,61,66 mortality patterns 65 radiologists compared with ophthal­

mologists 66 radionuclide 32,36-41,52 radionuclides, annual limits for intake

(ALI) 32, 36-41, 52 ALARA 28-30,41 classes D, Wand Y 37 compartmental models for respirato-

ry system and gastrointestinal tract 37

derived air concentrations (DAC) 37-41

handling of tritium targets 52 nonstochastic effects 36 radioactive clouds of gas 37 retention of compounds in the

pulmonary region 37 stochastic effects 36 tritiated thymidine 52 use of short-lived radionuclides 53 weighting factors for tissues 32, 36

radionuclides, cosmogenic 3 contribution to natural exposure 5

annual absorbed doses 5 annual body doses through inter­

nal radiation 5 annual intake 6

radionuclides, free limits of handling 41

radionuclides, groups of radiotoxicity (GRD 38-41

radionuclides in building materials 10 activity concentration 10 dose rates from indoor terrestrial

y-irradiation 10- 12 exposure indoors 10, 11 maximum permissible concentra­

tions 10 mean dose to the gonads 12

radionuclides, internal irradiation 3-8 radionuclides, limits for incorporation

(ingestion and inhalation) 34 ICRP scheme for determination of

dose equivalent 34, 35 deposition 35, 36 intake 35, 36 metabolic routes 35 uptake 35, 36

passage through organism 34 concept of transportability 34

radionuclides, naturally occurring in industrial products 21 enhanced natural sources of radia­

tion 1,22 annual effective dose equivalent

1,22 natural sources of radiation in areas

of normal backround 22 annual effective dose equivalent

22 unmodified 1,21

annual effective dose equivalent 21

averaged worldwide 21, 22 radionuclides, primordial 5

contribution to internal natural radiation exposure 5 annual absorbed doses 6-8 concentration in adults 6-8

radionuclides, unsealed handling in nuclear medicine 34 contaminations 34 external exposures 34 incorporation 34

radioprotective agents 99-101 against late radiation injury (late

effects) 115 cataract 116 damage in skin, muscle, and vas­

cular tissue 117 glomerulosclerosis, nephrosclero­

sis 117 tumors, leukemia, and lym­

phomas 115,116 biochemical mechanisms of action

130 biochemical shock 131 combination of radioprotectors

132 duration of action 132 effect of enzymes 132 efficacy of cyclic mononucleo-

tides 132 inhibitory effect on DNA synthe­

sis 131 noncyclic mononucleotides 132

Subject Index

specific receptors on plasma mem­brane, effect of receptor blok­kers 131

chromosome damage 114 clinical applications 123

against radiation sickness 123, 125

against side-effects of radiothera­py 123-125

curative effects 124 effects on lymphocyte counts, leu­

kocyte counts, platelet counts and aberration yields 125, 126

following radiotherapy 123-125 pharmacokinetic properties, toxici-

ty, maximum tolerated doses 125 prophylactic effects 124 radiation sickness 123, 125 radiotherapy 123, 124 side-effects in patients after radio-

protector infusion 125, 126 side-effects of radiotherapy 123,

125 dose that cause 50% lethality 100 dose-effect curves 98, 108, 109 effect against hematopoietic death,

gastrointestinal death and CNS death 105

effects in organs and tissues 105 digestive tract: crypt cells, small

intestine, and colon 109, 110 effect on cell of the bone marrow

and peripheral blood 107 gonads: testes and ovaries 111,

112 hematopoietic organs and blood

106 kidney 111 liver 111 lymphatic system and immune

responses 108 nervous system 113 protection factors 99, 108 protective effect 108 protective factors for skin and

bone marrow 105 respiratory tract 110 salivary gland 111 skin: erythema, edema, hair loss,

moist desquamation, and crust­ing 108

thyroid gland 111 radioprotective agents effect of route

of administration, solvent and pH range 101

oral use of radioprotective agents 102, 103

radioprotective effect 101, 103, 108

effect on radiation-induced develop­mental anomalies 114 congenital anomalies 115 fetal absorption 115 fetal weight 115 intrauterine death 115 neonatal and postnatal deaths 115

Subject Index

postnatal weight changes 115 suppression of brain 115 teratogenicity 115 testicular damage 115

effect of time 102 embryotoxicity 114 genetic studies 113

in vitro experiments on human lymphocytes 113

in vivo experiment in mammals 113

in man 97, 101, 102, 123-126 list of chemical compounds and

abbreviations 100, 107 mechanism of action (see also bio­

chemical-, pharmacodynamic-, and physiochemical mechanisms) 126 biogenic amines 126 nucleotides 126 sulfur-containing compounds

126 vitamins 126

pharmacodynamic mechanisms of action 128-130 anoxia of tissues 129 body temperature 130 decrease in oxygen consumption,

respiration, and rectal tempera­ture 129

effect of vasoconstrictive proper­ties 129

oxygen tension 129 prime determination: oxygen and

temperature 128, 130 temperature reduction 130 vasodilation 129

physiochemical mechanisms of action 126- 128 electron donor mechanism 127 formation of mixed disulfides with

plasma proteins 127 interaction with radiosensitive

structures of the cell 128 reaction with radiolysis products

of water 126 SH and SS groups 127 sulfhydryl groups bound to pro­

teins 127 superoxide dismutase (SOD) 127

survival rate 98, 102, 103, 106 delayed radioprotective effect 103

timing of administration and radia­tion exposure 102 fractionated irradiation 103 oral use 102, 103 prolonged exposure 102 single-dose irradiation 103

toxicity 99, 101 effective dose 99 in terms of drug dose per unit

body surface area and per unit body weight 101

protection factor (PF) 99 protective index (PI) 99 therapeutic index (TI) 101

tumor therapy 121-126 ascites tumors 122 cell carcinoma 12 Crocker sarcoma 121 Ehrlich carcinoma 121 in leukemia cells 123 solid tumors 122, 123 Walker rat carcinoma 121, 122

radioprotective chemicals occurring na­turally in mammals 130

radioprotective compounds (see also radioprotective agents) 104 survival rate 98, 102, 103, 106

radioprotective drugs (see also radio-protective agents) 97,99, 106

radioprotective effect and hyperther­mia 130

radioprotectors (see also radioprotec­tive agents) 102, 110 drug combination 110, 112

radioresistance 119, 121, 122, 127, 130-132 human cancer cells 101, 123-126,

131 studies in human medicine 101,

123-126, 132 radium dial workers, radiation carcino­

genesis 49, 67 epidemiologic studies 67 external radiation exposure 67 incorporated radium 67 increase in number of breast cancer

67 latency time 67 malignancy induced 67

radon 12, 14- 17, 20, 63, 64 building materials, exhalation rate

14-17 concentration 15 concentrations of radon and decay

products in- and outdoors 16 equilibrium factor in room air 17, 18 exhalation rate 15 in natural gas used in households 20 lung cancer risk for population 17,

18 mean resulting lung dose 17,18 potential a-energy 15

concentration of mixture of decay products 14, 15

power plant using geothermic energy release 20

radiation exposure by inhalation 12-18,20,63

room air exchange rate (ventilation rate) 16, 17

with the short-lived radon daughters 15-17,63,64

working level 14 radon daughter exposure and resultant

lung cancer 64 cigarette smoking 65 latent period 64

RBE factors 45,47, 119 exposures to y-rays 47 exposures to neutrons 47

149

reactor accident, contamination and decontamination of body surface 83 contamination of skin and clothing

83 decontamination process 83, 87 levels for decontamination of skin 84 measurements looking for contami-

nation 83 reactor accident, evacuation of the po­

pulation 81 reactor accident, prophylaxis of the thy­

roid gland 82, 83 reactor accidents, medical aspects

75-94 risk studies 77 - 80

reactor safety studies 77,83 German Reactor Safety Study 78 WASH 1400, Rasmussen 77

reference man 34, 36 source organs 36 target organs 36 weight of organs 36

relative biologic effectiveness (RBE) 45,47,119

release of radioactivity 75, 76, 79 repair mechanisms 47,49, 114

and immunologic reactions 47,49, 114

resistance 119, 122 risk estimates, risk factors 42, 45-48,

73,79 absolute risk model 46 average hereditary risk factor 47, 48

doubling dose 48 cancer induction 45, 79 cancer mortality risk estimates 46 cataracts 45 DS86 47 epidemiologic investigations 46,61,62

patients given radiotherapy 46 persons exposed during working

life 46,48,61 hereditary effects 45,47,48 incidence of harm from exposure

during pregnancy 45,47,48 incidence of leukemia 47,65 index of harm 42 linear quadratic relationship 44, 47 relative risk model 46 TD 65 47

risk factor 42, 45 -48, 73, 79 acute death 79 late injuries: cancer and genetic

damage 45, 79 proportional dose-effect relation­

ship 43, 45, 79 suggested by ICRP 42,45-48,73,79

22°Rn inhalation 13 222Rn inhalation 13

scavenger effect of radioprotectors 126, 127

scavenging mechanisms 113, 126, 127 sex-linked diseases 43, 47 short-lived decay products, potential

-energy 15

150

skin cancer after exposure 49, 61

smokers, daily intake 8 SMR 62,65,68, 70, 71 solar flares 2, 9 spleen colony technique 106 standardized mortality ration (SMR)

62,65,68,70 stochastic effects 31, 35, 36, 84 symptoms after acute whole body irra­

diation 27, 86, 87 therapeutic and prognostic conclu­

sions 27, 86

terrestrial radiation 2, 10- 12 areas with increased 3, 7 dose rates 3, 4 exposure indoors 11, 12

outdoor terrestrial y-irradiation 3, 4 sources 3

thoron 14 building materials, exhalation rate

14-17 concentration 15 concentrations of thoron and decay

products in- and outdoors 16 equilibrium factor in room air 17,

18 exhalation rate 15 lung cancer risk for population 17,

18,63 mean resulting lung dose 17, 18 potential a-energy 15 potential a-energy concentration of

mixture of decay products 14, 15

Subject Index

radiation exposure by inhalation 7, 12-18,20,63

room air exchange rate (ventilation rate) 16,17

working level 14 228Th, radioactive decay properties 14 Three Mile Island accident 79-81 thyroid gland carcinoma from incorpo-

ration of radioactive iodine 82 tolerance dose 26

UNSCEAR 28

workers in uranium mines 49, 63-65 working conditions, classification A

33, 50 classification B 33

X-ray hands 25, 61

Medical Radiology Diagnostic Imaging and Radiation Oncology

Edited by: L. W. Brady, Philadelphia; M. W. Donner Baltimore; H.-P. Heilmann, Hamburg; F. Heuck, Stuttgart

Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Hong Kong

J.H.Anderson, Johns Hopkins University, Baltimore, MD (Ed.)

Innovations in Diagnostic Radiology With contributions by numerous experts

Foreword by M. W. Donner, W. R. Brody, F. Heuck

1989. XIII, 212 pp. 144 figs., some in colour. Hardcover ISBN 3-540-19093-7

The current status and future applications of various diagnostic imaging procedures are discussed in this volume. The main focus is on research and development, in particular the potential they hold for further devel­opment and clinical application in various specialties. Those concerned with the academic growth of radiology as a discipline, such as basic scientists, young clinicians in training, and chairmen responsible for department planning, will be especially interested in the trends pre­sented here. The subject matter includes magnetic resonance imaging, interven­tional radiology, ultrasound, image analysis and management, positron emission tomography, and research training programs. The volume emphasizes the multidisciplinary direction of medical imaging; both basic scientists and clinicians in a wide variety of medical research areas should be aware of this tendency and the opportunities which will be available in the future.

R. R. Dobelbower, Jr., Medical College of Ohio, Toledo (Ed.)

Gastrointestinal Cancer Radiation Therapy

Foreword by L. W. Brady and H.-P. Heilmann

1989. XIV, 298 pp. 81 figs. 77 tabs. Hardcover ISBN 3-540-50505-9

The intricate role of radiation therapy in the management ofGI cancer is comprehensively reviewed in this timely volume. It offers unique coverage of the entire gastrointestinal tract, from the esophagus to the anus. Although the work focuses clearly on the radiotherapeutic man­agement of tumors of the GI tract, reviews of anatomy, epidemiology, and other pertinent topics are given. The volume is generally organized by disease site, but extensive special sections amplify important aspects related to GI cancer. These include the radiographic evaluation ofGI malignancy and tumor markers, an up-to-date review of chemothera­peutic treatment of gut cancers, and patient follow-up. Edited by an internationally known leader in the field of radiotherapy, this volume represents a compilation of years of research and experience utilizing today's technology and state-of-the-art techniques.

Medical Radio ogy Diagnostic Imaging and Radiation Oncology

Edited by: L. W.Brady, Philadelphia; M. W. Donner, Baltimore; H.-P. Heilmann, Hamburg; F. Huck. Stuttgart

Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Hong Kong

G.E.Laramore, University of Washington (Ed.)

Radiation Therapy of Head and Neck Cancer Foreword by L. w. Brady and H.-P. Heilmann

1989. XII, 237 pp. 123 figs. Hardcover ISBN 3-540-19360-X

This volume considers the treatment of head and neck cancer from the point of view of the radiation oncologist. The epidemiology of head and neck cancer, evaluation of the patient, and basic treatment issues are discussed and the separate chapters are devoted to specific head and neck sites. The book provides a valuable summary of treatment approaches and results representing the best standard of care in the United States, Canada, and Europe. It offers a consensus approach and does not set forth the particular attitudes of any single institution. A comprehensive survey of the relevant literature is presented at the end of each chapter. Material is treated in such a way as to be relevant both to the practicing clinician and the resident in training.

H.R. Withers, University of California at Los Angeles; L. J. Peters, University of Texas (Eds.)

Innovations in Radiation Oncology With contributions by numerous experts

Foreword by L. W. Brady and H.-P. Heilmann

1987. XVII, 329 pp. III figs. Hardcover ISBN 3-540-17818-X

Contents: General Aspects. - Conservation Therapy. - Extended Field Therapy. - Restricted Field Therapy. - New Imaging Technologies and Radiotherapy. - Modified Fractionation. - Drugs and Radiation. -Neutrons. - Adjunctive Therapies. - Subject Index.

C. W. Scarantino, Wake Forest University, Winston-Salem (Ed.)

Lung Cancer Diagnostic Procedures and Therapeutic Management with Special Reference to Radiotherapy

With contributions by numerous experts

1985. XI, 173 pp. 42 figs. Hardcover ISBN 3-540-13176-0

This up-to-date reference book covers a broad range of topics regarding lung cancer. There is an extensive review of recent epidemiological and early detection studies, as well as of current histological observations of the tumor hetero­geneity of lung cancer. It presents an up-to-date examination of the latest clinical developments in diagnosis and treatment as well as results of clini­cal trials employing irradiation chemotherapy and surgery.